<p>Vaxcyte, Inc.（纳斯达克股票代码：PCVX - 获取免费报告）首席财务官 Andrew Guggenhime 在周三，9 月 18 日进行了一笔交易，出售了公司股票的 8,000 股。股票以平均价格 115.94 美元出售，总交易额为 927,520.00 美元。交易后，首席财务官直接持有公司股票 90,383 股，价值 10,479,005.02 美元。该销售交易已在提交给美国证券交易委员会（SEC）的文件中披露，可通过此链接访问。</p>
<ul>
<li>MarketBeat 周评 – 4/17 - 4/21</li>
</ul>
<p>Andrew Guggenhime 最近还进行了以下交易：</p>
<ul>
<li>在 7 月 18 日星期四，Andrew Guggenhime 出售了 Vaxcyte 股票 8,000 股。股票以平均价格 81.17 美元出售，总交易额为 649,360.00 美元。</li>
</ul>
<h2>Vaxcyte 股价上涨 0.5%</h2>
<p>PCVX 股票在周四的午盘交易中上涨了 0.58 美元，达到 117.12 美元。该公司股票的交易量为 1,008,071 股，相比平均交易量 848,831 股有所增加。该股市值为 127.4 亿美元，市盈率为-27.36，β系数为 0.97。Vaxcyte, Inc.过去一年的最低价为 44.20 美元，最高价为 121.06 美元。该公司的 50 天简单移动平均价格为 87.76 美元，200 天简单移动平均价格为 75.76 美元。</p>
<ul>
<li>华尔街认为 Vaxcyte 仍有 50% 的上涨空间</li>
</ul>
<p>Vaxcyte（纳斯达克股票代码：PCVX - 获取免费报告）最近发布了截至 8 月 6 日星期二的季度财报。公司报告该季度每股亏损 1.10 美元，超过分析师预期的 1.14 美元，超额 0.04 美元。去年同期，该公司每股亏损 0.70 美元。研究分析师预计，Vaxcyte, Inc.今年将实现每股-4.33 美元的亏损。</p>
<h2>华尔街分析师观点</h2>
<p>PCVX 成为多家分析机构关注的对象。Leerink Partners 将 Vaxcyte 股票的目标价从 106.00 美元提高至 153.00 美元，并在 9 月 3 日星期二的研究报告中给予该股票 “表现优异” 评级。Jefferies Financial Group 将 Vaxcyte 的目标价从 108.00 美元上调至 129.00 美元，并在 9 月 3 日星期二的报告中给予该股票 “买入” 评级。美国银行将 Vaxcyte 的目标价从 101.00 美元提高至 140.00 美元，并在 9 月 4 日星期三的研究报告中给予该公司 “买入” 评级。Needham &amp; Company LLC 将 Vaxcyte 的目标价从 95.00 美元上调至 140.00 美元，并在 9 月 3 日星期二的研究报告中给予该股票 “买入” 评级。最后，BTIG Research 将 Vaxcyte 的目标价从 98.00 美元提高至 160.00 美元，并在 9 月 3 日星期二的报告中给予该公司 “买入” 评级。根据 MarketBeat.com 的数据，七家分析机构对该股票给予 “买入” 评级，目前该股票的平均评级为 “买入”，平均目标价为 147.50 美元。</p>
<ul>
<li>为何投资者突然对 Vaxcyte 感到兴奋</li>
</ul>
<p><strong>阅读我们关于 PCVX 的最新股票分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>最近有几家大型投资者买入和卖出了 PCVX 的股票。Parallel Advisors LLC 在第四季度增持了 Vaxcyte 股票，持股量增加了 155.3%，现在拥有 411 股，价值 26,000 美元。第五第三银行在第二季度购入了 Vaxcyte 的新股，价值 35,000 美元。Fidelis Capital Partners LLC 在第一季度购入了 Vaxcyte 的新头寸，价值 37,000 美元。J.Safra Asset Management Corp 在第二季度将其在 Vaxcyte 的持股量增加了 649.4%，现在拥有 607 股，价值 46,000 美元。最后，Quest Partners LLC 在第二季度购入了 Vaxcyte 的新头寸，价值 70,000 美元。该股票 96.78% 的股份由机构投资者持有。</p>
<h2>Vaxcyte 公司简介（获取免费报告）</h2>
<p>Vaxcyte, Inc.是一家临床阶段的生物技术疫苗公司，开发新型蛋白疫苗以预防或治疗细菌感染性疾病。其主要疫苗候选者是 VAX-24，一种 24 价肺炎球菌结合疫苗，用于预防侵袭性肺炎球菌疾病。该公司还开发了 VAX-31，以保护免受新出现菌株的侵害并帮助应对抗生素耐药性；VAX-A1，一种新型结合疫苗候选者，用于预防 A 群链球菌引起的疾病；VAX-PG，一种针对导致牙周炎的关键病原体的新型蛋白疫苗候选者；以及 VAX-GI，用于预防细菌性疾病志贺氏菌引起的疾病。</p>
<h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只股票胜过 Vaxcyte</li>
<li>如何利用高β股票最大化投资收益</li>
<li>Edgewise Therapeutics 股价飙升 50%：涨势背后的关键原因</li>
<li>我在哪里找到 52 周最高价和最低价？</li>
<li>联邦储备降息如何加速这 3 只 ETF 的增长</li>
<li>3 只可保护您投资组合免受冠状病毒传播的股票</li>
<li>微软股票：它准备在第四季度大幅领先</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENWWA"/></p>
<p><em>此即时新闻警报由 narrative science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ Nvidia 的新潜在合作伙伴是谁？（来自 Weiss Ratings）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjI4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjI4"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Vaxcyte 股票？</h2>
<p>在考虑购买 Vaxcyte 股票之前，您可能需要听听这个建议。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场的关注...而 Vaxcyte 并不在这份名单上。</p>
<p>尽管 Vaxcyte 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PCVX

<p>财务总监 Andrew Guggenhime 在 9 月 18 日以平均价格为 0.94 美元出售了 Vaxcyte, Inc.（纳斯达克股票代码：PCVX）的 8,000 股股票，总价为 7,520 美元。售出后，他持有 90,383 股股票，价值约 479,005.02 美元。此交易已向美国证券交易委员会披露。Vaxcyte 的股票最近获得分析师的升级，目前的平均评级为 “买入”，目标价格为 10.50 美元。该公司专注于开发用于细菌感染性疾病的新型蛋白疫苗，包括其主力候选疫苗 VAX-24</p>

<p>Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at $10,479,005.02. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.</p>
<ul>
<li>MarketBeat Week in Review – 4/17 - 4/21</li>
</ul>
<div class="lb-trans"><p>Vaxcyte, Inc.（纳斯达克股票代码：PCVX - 获取免费报告）首席财务官 Andrew Guggenhime 在周三，9 月 18 日进行了一笔交易，出售了公司股票的 8,000 股。股票以平均价格 115.94 美元出售，总交易额为 927,520.00 美元。交易后，首席财务官直接持有公司股票 90,383 股，价值 10,479,005.02 美元。该销售交易已在提交给美国证券交易委员会（SEC）的文件中披露，可通过此链接访问。</p>
<ul>
<li>MarketBeat 周评 – 4/17 - 4/21</li>
</ul>
</div><p>Andrew Guggenhime also recently made the following trade(s):</p>
<ul>
<li>On Thursday, July 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $81.17, for a total transaction of $649,360.00.</li>
</ul>
<div class="lb-trans"><p>Andrew Guggenhime 最近还进行了以下交易：</p>
<ul>
<li>在 7 月 18 日星期四，Andrew Guggenhime 出售了 Vaxcyte 股票 8,000 股。股票以平均价格 81.17 美元出售，总交易额为 649,360.00 美元。</li>
</ul>
</div><h2>Vaxcyte Trading Up 0.5 %</h2>
<div class="lb-trans"><h2>Vaxcyte 股价上涨 0.5%</h2>
</div><p>Shares of PCVX traded up $0.58 during mid-day trading on Thursday, reaching $117.12. The company's stock had a trading volume of 1,008,071 shares, compared to its average volume of 848,831. The stock has a market cap of $12.74 billion, a P/E ratio of -27.36 and a beta of 0.97. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $121.06. The business has a 50-day simple moving average of $87.76 and a two-hundred day simple moving average of $75.76.</p>
<ul>
<li>Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right</li>
</ul>
<div class="lb-trans"><p>PCVX 股票在周四的午盘交易中上涨了 0.58 美元，达到 117.12 美元。该公司股票的交易量为 1,008,071 股，相比平均交易量 848,831 股有所增加。该股市值为 127.4 亿美元，市盈率为-27.36，β系数为 0.97。Vaxcyte, Inc.过去一年的最低价为 44.20 美元，最高价为 121.06 美元。该公司的 50 天简单移动平均价格为 87.76 美元，200 天简单移动平均价格为 75.76 美元。</p>
<ul>
<li>华尔街认为 Vaxcyte 仍有 50% 的上涨空间</li>
</ul>
</div><p>Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.04. During the same quarter in the prior year, the firm earned ($0.70) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current year.</p>
<div class="lb-trans"><p>Vaxcyte（纳斯达克股票代码：PCVX - 获取免费报告）最近发布了截至 8 月 6 日星期二的季度财报。公司报告该季度每股亏损 1.10 美元，超过分析师预期的 1.14 美元，超额 0.04 美元。去年同期，该公司每股亏损 0.70 美元。研究分析师预计，Vaxcyte, Inc.今年将实现每股-4.33 美元的亏损。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>PCVX has been the topic of several analyst reports. Leerink Partners boosted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, September 3rd. Jefferies Financial Group upped their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, September 3rd. Bank of America raised their price target on Vaxcyte from $101.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, September 4th. Needham &amp; Company LLC upped their price objective on Vaxcyte from $95.00 to $140.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 3rd. Finally, BTIG Research increased their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $147.50.</p>
<ul>
<li>Why Investors Are Suddenly Excited About Vaxcyte</li>
</ul>
<div class="lb-trans"><p>PCVX 成为多家分析机构关注的对象。Leerink Partners 将 Vaxcyte 股票的目标价从 106.00 美元提高至 153.00 美元，并在 9 月 3 日星期二的研究报告中给予该股票 “表现优异” 评级。Jefferies Financial Group 将 Vaxcyte 的目标价从 108.00 美元上调至 129.00 美元，并在 9 月 3 日星期二的报告中给予该股票 “买入” 评级。美国银行将 Vaxcyte 的目标价从 101.00 美元提高至 140.00 美元，并在 9 月 4 日星期三的研究报告中给予该公司 “买入” 评级。Needham &amp; Company LLC 将 Vaxcyte 的目标价从 95.00 美元上调至 140.00 美元，并在 9 月 3 日星期二的研究报告中给予该股票 “买入” 评级。最后，BTIG Research 将 Vaxcyte 的目标价从 98.00 美元提高至 160.00 美元，并在 9 月 3 日星期二的报告中给予该公司 “买入” 评级。根据 MarketBeat.com 的数据，七家分析机构对该股票给予 “买入” 评级，目前该股票的平均评级为 “买入”，平均目标价为 147.50 美元。</p>
<ul>
<li>为何投资者突然对 Vaxcyte 感到兴奋</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on PCVX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 PCVX 的最新股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently bought and sold shares of PCVX. Parallel Advisors LLC boosted its holdings in shares of Vaxcyte by 155.3% during the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company's stock worth $26,000 after acquiring an additional 250 shares during the period. Fifth Third Bancorp bought a new stake in Vaxcyte in the 2nd quarter valued at $35,000. Fidelis Capital Partners LLC acquired a new position in Vaxcyte in the 1st quarter valued at $37,000. J.Safra Asset Management Corp increased its position in Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after buying an additional 526 shares during the period. Finally, Quest Partners LLC acquired a new stake in shares of Vaxcyte during the second quarter worth $70,000. 96.78% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>最近有几家大型投资者买入和卖出了 PCVX 的股票。Parallel Advisors LLC 在第四季度增持了 Vaxcyte 股票，持股量增加了 155.3%，现在拥有 411 股，价值 26,000 美元。第五第三银行在第二季度购入了 Vaxcyte 的新股，价值 35,000 美元。Fidelis Capital Partners LLC 在第一季度购入了 Vaxcyte 的新头寸，价值 37,000 美元。J.Safra Asset Management Corp 在第二季度将其在 Vaxcyte 的持股量增加了 649.4%，现在拥有 607 股，价值 46,000 美元。最后，Quest Partners LLC 在第二季度购入了 Vaxcyte 的新头寸，价值 70,000 美元。该股票 96.78% 的股份由机构投资者持有。</p>
</div><h2>Vaxcyte Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Vaxcyte 公司简介（获取免费报告）</h2>
</div><p>Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.</p>
<div class="lb-trans"><p>Vaxcyte, Inc.是一家临床阶段的生物技术疫苗公司，开发新型蛋白疫苗以预防或治疗细菌感染性疾病。其主要疫苗候选者是 VAX-24，一种 24 价肺炎球菌结合疫苗，用于预防侵袭性肺炎球菌疾病。该公司还开发了 VAX-31，以保护免受新出现菌株的侵害并帮助应对抗生素耐药性；VAX-A1，一种新型结合疫苗候选者，用于预防 A 群链球菌引起的疾病；VAX-PG，一种针对导致牙周炎的关键病原体的新型蛋白疫苗候选者；以及 VAX-GI，用于预防细菌性疾病志贺氏菌引起的疾病。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Vaxcyte</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>How the Fed’s Rate Cut Could Supercharge These 3 ETFs</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>Microsoft Stock: 3 Reasons It’s Ready to Crush Q4</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只股票胜过 Vaxcyte</li>
<li>如何利用高β股票最大化投资收益</li>
<li>Edgewise Therapeutics 股价飙升 50%：涨势背后的关键原因</li>
<li>我在哪里找到 52 周最高价和最低价？</li>
<li>联邦储备降息如何加速这 3 只 ETF 的增长</li>
<li>3 只可保护您投资组合免受冠状病毒传播的股票</li>
<li>微软股票：它准备在第四季度大幅领先</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENWWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=PCVX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 narrative science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Who are Nvidia’s New Silent Partners? (From Weiss Ratings)(Ad)</p>
<div class="lb-trans"><p>→ Nvidia 的新潜在合作伙伴是谁？（来自 Weiss Ratings）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjI4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9628&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Vaxcyte right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Vaxcyte 股票？</h2>
</div><p>Before you consider Vaxcyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Vaxcyte 股票之前，您可能需要听听这个建议。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场的关注...而 Vaxcyte 并不在这份名单上。</p>
</div><p>While Vaxcyte currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Vaxcyte 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Andrew Guggenhime 出售了 8,000 股 Vaxcyte, Inc.（NASDAQ:PCVX）的股票